REMAP-CAP
Randomised, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP)
Type: Interventional
Site and lead:
- Oxford Road Campus: Dr Jonathan Bannard-Smith
- Wythenshawe Hospital: Dr Peter Alexander
Patient group: COVID-19 patients in ICU
Intervention:
- Lopinavir/ritonavir
- Anakinra
- Convalescent Plasma
Funder: European Commission
Sponsor: University Medical Centre Utrecht (Netherlands)
More about REMAP-CAP
- REMAP-CAP is a nationally-prioritised COVID-19 study. See the full list Urgent Public Health COVID-19 Studies on the NIHR website.
- Read more about our first patient recruited to REMAP-CAP at MFT.
The primary purpose of this study is to generate evidence that can be applied during the coronavirus pandemic in order to reduce deaths, Intensive Care Unit (ICU) use, and morbidity in severely ill patients with COVID-19 infection.
It is a fully adaptive, platform trial, meaning several different treatments can be tested at the same time under one ‘platform’ – and more treatments can be added as new evidence emerges.
